A Cannabis Company Wants to Make a $ 450 Million Deal with the Taliban

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN


A German company wants to invest $ 450 million in cannabis farms in Taliban-controlled Afghanistan.

Cpharm, a German-based cannabis company currently operating in Australia, is looking to strike a deal with the Taliban to grow cannabis in Afghanistan.

Cpharm is Determined to Plant Roots in Afghanistan

The trade deal is currently on hold due to Cpharm’s founder and CEO, Werner Zimmerman, receiving death threats from European drug cartels. His long-term friend, now Kyrgyzstan’s interior minister, has offered advice against his ambitions within the region, according to Vice.

Undeterred by threats and advice against doing business in Afghanistan, Zimmerman is confident the plan to invest in the region will yield results. the company plans to use the middle-eastern nation as a base to distribute cannabis products to western European countries including Germany, which may be on the brink of legalizing the plant for adult use.

Fertile Ground

Afghanistan is an ideal country for cannabis farmers, as the plant is native to the region and can grow year-round. However, cannabis companies have largely avoided the country due to its ongoing political instability. Cpharm’s designs on the region and looming deal with the Taliban – an organization not recognized as a legitimate political party by much of Europe – did not go unnoticed, despite Cpharm’s best efforts.

Last November, the company Chief Financial Officer, Tony Gabites publicly denied having ever connected with the Taliban and called the rumors’ media lies‘”According to CannabisLifeNetwork.

Despite the public relations campaign in 2021 to play down the deal, recent news confirms the rumors were true.

International Concerns

People from the public and private sectors in Europe are also raising concerns about further legitimizing the Taliban by providing relief from sanctions through private investments.

“There is also the obvious concern that an injection of capital will enrich and empower the highly problematic Taliban regime – which is the reason why traditional aid donors have been very reluctant to return to Afghanistan since the allied withdrawal, despite the obvious needs of Afghan people. , ”Said Steve Rolles, a senior policy analyst with the Transform drug policy foundation in the UK.

Cpharm has already established a presence in countries in the region including Lesotho, Morocco Morocco, Kyrgyzstan, North Macedonia, and Cyprus, with the project at Kazakhstan raking up over a $ 500 million investment.





Source link

TheHealthReporter

TheHealthReporter

Recent Posts

Enhance your Cisco HIMSS24 experience
The Cisco Customer Experience Healthcare Practice helps customers leverage the use of Cisco technology...
Read More
HIMSS 2024 Find out before you go
The future of healthcare is coming into focus! Now more than ever, we believe that technology is a critical...
Read More
How GLP-1 Drug Success Is Transforming Healthcare Revenue: Is Your Organization Ready?
The huge revenue opportunity arising from the recent success of GLP-1 drugs is not just for pharmaceutical...
Read More

Related Posts